BioMarin Acquiring Amicus — Both Great Companies, Only One Worth Buying Now (NASDAQ:BMRN)

On December 19th, BioMarin Pharmaceutical Inc. ( BMRN ) announced it is acquiring Amicus Therapeutics, Inc. ( FOLD ) at $14.50 per share. The transaction is expected to take effect in Q2 2026. This article covers both companies, but sinceAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensa ...